Please assess the completion status of the following clinical trial:

Trial Title: HIV Vaccine Study in HIV Positive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects age 18 - 50 years inclusive with HIV-1 infection~* Documented as HIV positive, with viral loads higher than 5,000 copies per millilitre of blood, but less than 500,000 using either a branched DNA test, or an RT-PCR test~* CD4 T cell count \>350/mm3~* Clinically stable in the opinion of the investigator and not expected to require anti-retroviral therapy during the course of the study~* No evidence of any AIDS defining illness~* Subjects with male or female partners must agree to use a barrier method of protection against disease transmission during intercourse (e.g. condom).~* Subjects whose female partners are of child-bearing potential must also agree to use a second contraceptive method (e.g. spermicidal agent, IUD, hormonal contraceptive) in addition to a condom for the duration of the study.~* Provide written informed consent to participate in the study and be willing to comply with all study procedures.~Exclusion Criteria:~* Participation in a clinical trial or receipt of an experimental therapy within 30 days prior to study dosing~* Receipt of another vaccine 30 days before or 30 days after HIV-v~* Currently receiving anti-viral, anti-retroviral therapy or any chronic anti-infective therapy~* Receiving, or have received over the previous two weeks, any treatment that might modulate the immune response after vaccination, including, but not limited to, immunosuppressive therapy and systemic corticosteroids~* Suffers from a disease or is undergoing treatment that can affect immune response such as systemic or high dose inhaled corticosteroids (\>800µg/day beclometasone or equivalent), radiation treatment or cytotoxic drugs~* Received a blood transfusion or immunoglobulins within 90 days prior to study entry~* Patients on inhaled corticosteroids for asthma or other respiratory conditions~* Subjects having an infective exacerbation during the screening process as defined as a requirement of inhaled, oral, or intravenous antibiotics prior to the first study dose will be excluded~* Use of non-steroidal anti-inflammatory drugs (NSAIDs) or any over-the-counter product, herbal product, diet aid, hormone supplement, etc., within 14 days prior to vaccination or any planned administration of these products over the course of the first 28 days after vaccination (unless approved by both the Principal Investigator and the Sponsor)~* Patients with Hepatitis B or C co-infection (though serological evidence of previous hepatitis C infection with no evidence of carrier status is acceptable)~* Suffers from or has a history of significant neurological, cardiovascular, pulmonary (including asthma), hepatic, metabolic, rheumatic, autoimmune, haematological or renal disorder~* Subjects with clinically significant out of range laboratory values as stated in Section 8.6 of the protocol~* Patients with a history of significant or allergic reaction to vaccines~* Patients with a known or suspected dependence on illicit drugs or alcohol and those undergoing illicit drug replacement programmes~* Is direct employee of the study site or monitoring CRO

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Low Dose HIV-v with water for injection
- Group 2 (Type: EXPERIMENTAL): Low Dose HIV-v with adjuvant
- Group 3 (Type: EXPERIMENTAL): High Dose HIV-v with water for injection
- Group 4 (Type: EXPERIMENTAL): High Dose HIV-v with adjuvant
- Group 5 (Type: PLACEBO_COMPARATOR): Control group: adjuvant only or water for injection only

Based on this trial design, predict the completion outcome and termination type (if applicable).